Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for Kyntra Bio (KYNB) over the last 10 years, with Q4 2024 value amounting to $2.3 million.

  • Kyntra Bio's Gains from Sales and Divestitures rose 1258.74% to $2.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.3 million, marking a year-over-year increase of 1258.74%. This contributed to the annual value of $2.3 million for FY2024, which is 1258.74% up from last year.
  • Kyntra Bio's Gains from Sales and Divestitures amounted to $2.3 million in Q4 2024, which was up 1258.74% from $2.0 million recorded in Q4 2023.
  • Over the past 5 years, Kyntra Bio's Gains from Sales and Divestitures peaked at $2.3 million during Q4 2024, and registered a low of $813000.0 during Q4 2020.
  • For the 5-year period, Kyntra Bio's Gains from Sales and Divestitures averaged around $1.4 million, with its median value being $1.1 million (2022).
  • In the last 5 years, Kyntra Bio's Gains from Sales and Divestitures skyrocketed by 184.5% in 2021 and then soared by 7530.65% in 2023.
  • Quarter analysis of 5 years shows Kyntra Bio's Gains from Sales and Divestitures stood at $813000.0 in 2020, then grew by 1.85% to $828000.0 in 2021, then surged by 37.92% to $1.1 million in 2022, then soared by 75.31% to $2.0 million in 2023, then rose by 12.59% to $2.3 million in 2024.
  • Its Gains from Sales and Divestitures stands at $2.3 million for Q4 2024, versus $2.0 million for Q4 2023 and $1.1 million for Q4 2022.